Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Medical malpractice litigation is often complex, in-depth, and issue-heavy. Mass tort litigation is also often complex, in-depth, and issue-heavy. What happens when those two areas of practice converge during the course of a case? The answer to that question depends, of course, on the facts of each specific case. However, the issues that face attorneys on all sides of the litigation cannot be ignored.
Mass tort claims are typically claims made by individual plaintiffs against a manufacturer of a pharmaceutical or medical device. Prescription drugs require a treating physician's prescription to the patient and medical devices require the treating surgeon to decide to use the particular device. The role of the treating physician, therefore, is integral to the treatment of the patients in these claims. A physician's prescription of a drug or use of a device that is or at some point becomes the subject of a mass tort claim, however, does not always amount to malpractice. As a lawyer representing a potential plaintiff, manufacturer, or treating physician, you cannot ignore the actions and the role the treating physician played in the patient's treatment involving the drug or device.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.